natgillin/translations-raw huggingface dataset:
There is no evidence that varicella vaccine virus is excreted in breast milk. 
Ni dokazov, da se cepilni virus noric izloča v materinem mleku.
To ensure optimal protection against chickenpox and measles, two doses of ProQuad should be given at least three months apart. 
Za zagotovitev optimalne zaščite proti noricam in ošpicam morajo med prvim in drugim odmerkom cepiva ProQuad miniti vsaj 3 meseci.
Children who received 2 doses of ProQuad intramuscularly or subcutaneously In a clinical trial, 405 children received 2 doses of ProQuad, either by the intramuscular or subcutaneous route of administration. 
V kliničnem preskušanju je 405 otrok prejelo 2 odmerka cepiva ProQuad, bodisi intramuskularno ali subkutano.
After reconstitution, 1 dose (0.5 ml) contains (live, attenuated): 
Po pripravi cepiva 1 odmerek (0,5 ml) vsebuje (živ, oslabljen):
In 2 clinical trials, 1035 subjects were administered a second dose of ProQuad approximately 3 months after the first dose. 
Otroci, ki so dobili drugi odmerek cepiva ProQuad V 2 kliničnih preskušanjih je 1035 oseb dobilo drugi odmerek cepiva ProQuad približno 3 mesece po prvem cepljenju.
Musculoskeletal, connective tissue and bone disorders Arm pain, Musculoskeletal stiffness 
Bolezni mišično-skeletnega sistema in vezivnega tkiva bolečina v rokah, mišično-skeletna okorelost redki
Skin and subcutaneous tissue disorders Measles-like rash 
Bolezni kože in podkožja ošpicam podoben izpuščaj
Solvent for ProQuad 
Vehikel za ProQuad
The rates and types of adverse reactions seen in the study group that received ProQuad were generally similar to those seen in the groups that received Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. (see section 5.1 for study description). 
Deleži in vrste neželenih učinkov, ki so jih opazili v preučevani skupini, ki je bila cepljena s cepivom ProQuad, so bili na splošno podobni tistim, ki so jih opazili v skupinah, ki sta dobili cepivo z živim virusom noric (Oka/Merck) in cepivo proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc. (glejte poglavje 5.1 za opis študije).
In addition, cases of thrombocytopenia have been reported after primary vaccination or revaccination with measles vaccine; measles, mumps, and rubella vaccine; and varicella vaccine. 
Poleg tega so o primerih trombocitopenije poročali tudi po primarnem cepljenju oziroma po ponovnem cepljenju s cepivom proti ošpicam, s cepivom proti ošpicam, mumpsu in rdečkam ter s cepivom proti noricam.
In addition, a decrease by approximately 90% (approximately 10-fold) in varicella hospitalization rates was observed in all age groups. 
Poleg tega so v vseh starostnih skupinah opazili zmanjšanje hospitalizacij zaradi noric za približno 90 % (približno 10-kratno).
The most common adverse events reported with the use of ProQuad were: injection-site reactions including pain/tenderness/soreness, redness, swelling or bruising; fever (≥39.4°C rectal equivalent); irritability; rash (including measles-like rash, varicella-like rash, and injection-site rash); upper respiratory infection; vomiting and diarrhoea. 
Najbolj pogosti neželeni dogodki, o katerih so poročali pri uporabi cepiva ProQuad, so bili: reakcije na mestu injiciranja, ki vključujejo bolečino/občutljivost/bolečnost, rdečino, oteklino ali modrice; zvišana telesna temperatura (ekvivalentno ≥ 39,4 °C rektalno); razdražljivost; izpuščaj (vključno z ošpicam podobnim izpuščajem, noricam podobnim izpuščajem in izpuščajem na mestu injiciranja); okužba zgornjih dihal; bruhanje in driska.
The antibody persistence rates 1 year postvaccination in recipients of a single dose of ProQuad were 98.9% (1722/1741) for measles, 96.7% (1676/1733) for mumps, 99.6% (1796/1804) for rubella, and 97.5% (1512/1550) for varicella (≥5 gpELISA Units/ml). 
Eno leto po cepljenju so se protitelesa (≥ 5 gpELISA enot/ml) proti ošpicam ohranila pri 98,9 % (1.722/1.741) prejemnikov enega odmerka cepiva ProQuad, protitelesa proti mumpsu pri 96,7 % (1.676/1.733), proti rdečkam pri 99,6 % (1.796/1.804) in protitelesa proti noricam pri 97,5 % (1.512/1.550) prejemnikov.
After reconstitution, one dose (0.5 ml) contains: The active substances are: 
Po pripravi en odmerek (0,5 ml) vsebuje: Učinkovine so:
Evaluation of immunogenicity in children from 9 to 12 months of age at the time of first dose A clinical study was conducted with ProQuad administered with a 2-dose schedule, the doses being given 3 months apart in 1,620 healthy subjects from 9 to 12 months of age at the time of first dose. 
Ocena imunogenosti pri otrocih, ki so bili ob prejetju prvega odmerka stari od 9 do 12 mesecev Pri 1.620 zdravih osebah, ki so bile ob prejetju prvega odmerka stare od 9 do 12 mesecev, so izvedli klinično študijo, v kateri so s cepivom ProQuad cepili v 2 odmerkih, v razmiku 3 mesecev.
ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. 
Cepivo ProQuad je indicirano za hkratno cepljenje proti ošpicam, mumpsu, rdečkam in noricam v starosti od 12 mesecev dalje.
Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination. 
Pri večini cepljenih, za rdečke dovzetnih posameznikov, je 7 do 28 dni po cepljenju prišlo do izločanja majhnih količin živega oslabljenega virusa rdečk iz nosu ali grla.
The general safety profiles of the IM and SC administration routes were comparable; however, fewer subjects experienced injection-site adverse reactions in the IM group after each dose (see section 5.1 for study description). 
Otroci, ki so cepivo ProQuad prejeli intramuskularno Splošna varnostna profila intramuskularne in subkutane aplikacije sta bila primerljiva, vendar so se v skupini, ki je cepivo prejela intramuskularno, neželeni učinki na mestu vboda po vsakem odmerku pojavili pri manjšem številu oseb (za opis študije glejte poglavje 5.1).
Measles (titre ≥255 mIU/mL) 
Ošpice (titer ≥ 255 mi.e./ml)
In severely immunocompromised individuals inadvertently vaccinated with measles-containing vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infection have been reported. 
Pri hudo imunsko oslabljenih osebah, ki so jih pomotoma cepili s cepivom, ki vsebuje virus ošpic, so poročali o ošpičnem encefalitisu z inkluzijskimi telesci, pnevmonitisu in smrti kot neposredni posledici razsejane okužbe s cepilnim virusom ošpic.
• Uncommon (may affect up to 1 in 100 people): seizures with a fever. 
• Občasni (pojavijo se lahko pri največ 1 od 100 oseb): krči z zvišano telesno temperaturo;
General disorders and administration site conditions Fever 
Splošne težave in spremembe na mestu aplikacije zvišana telesna temperatura
The immunogenicity of a single dose of an earlier formulation of ProQuad was comparable to the immunogenicity of a single dose of its individual component vaccines (Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc.), currently used in routine vaccination in some countries. 
Imunogenost enkratnega odmerka predhodne oblike cepiva ProQuad je bila primerljiva z imunogenostjo enkratnega odmerka posameznih komponent cepiva (cepivo z živim virusom noric (Oka/Merck) ter cepivo proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc.), ki se trenutno v nekaterih državah uporabljajo za rutinsko cepljenje.
If you forget to take ProQuad 
Če pozabite na cepljenje s cepivom ProQuad
Atypical measles, Encephalitis*, Epididymitis, Herpes zoster*, Infection, Measles, Orchitis, Parotitis 
, virusni konjunktivitis redki aseptični meningitis*, atipične ošpice, encefalitis*, epididimitis, herpes zoster*, okužba, ošpice, orhitis, parotitis neznana pogostnost
The doctor will decide if ProQuad should be given. 
Zdravnik se bo odločil, ali jih sme cepiti s cepivom ProQuad.
ProQuad with Solvent for reconstitution supplied in a Vial: 
Cepivo ProQuad z vehiklom za rekonstitucijo v viali:
The vaccine may be administered to persons from 12 months of age. 
Cepimo lahko v starosti od 12 mesecev dalje.
In addition, individuals who experienced thrombocytopenia following the first dose of a live measles, mumps, and rubella vaccine may develop thrombocytopenia with repeat doses. 
Poleg tega se lahko pri posameznikih, pri katerih se je trombocitopenija pojavila po prvem odmerku živega cepiva proti ošpicam, mumpsu in rdečkam, trombocitopenija pojavi tudi po ponovnih odmerkih.
In clinical trials, no cases were reported regarding the development or worsening of thrombocytopenia in individuals vaccinated with ProQuad. 
V kliničnih preskušanjih niso poročali o nobenem primeru nastanka ali poslabšanja trombocitopenije pri posameznikih, ki so bili cepljeni s cepivom ProQuad, so pa o primerih trombocitopenije poročali v okviru postmarketinških izkušenj po primarnem cepljenju s cepivom ProQuad.
The geometric mean titers (GMTs) following the second dose of ProQuad increased approximately 2 fold each for measles, mumps, and rubella, and approximately 41 fold for varicella (for safety information, see section 4.8). 
GMT protiteles proti ošpicam, mumpsu in rdečkam so se po drugem odmerku cepiva ProQuad približno podvojila, proti noricam pa so se povečala za približno 41-krat (za podatke o varnosti glejte poglavje 4.8).
ProQuad, when reconstituted, is clear pale yellow to light pink liquid. 
Ko je cepivo ProQuad pripravljeno, je bistra, bledo rumena do svetlo rožnata tekočina.
Studies have not been conducted with ProQuad in pregnant women. 
Študij o cepljenju s cepivom ProQuad pri nosečnicah niso izvedli.
After vaccination with ProQuad, IG or VZIG should not be given for 1 month, unless your doctor tells you otherwise. 
Po cepljenju s cepivom ProQuad cepljena oseba 1 mesec ne sme dobiti imunoglobulinov ali imunoglobulina proti virusu varicella-zoster, razen če se zdravnik ne odloči drugače.
ProQuad is a vaccine containing measles, mumps, rubella, and varicella (chickenpox) viruses that have been weakened. 
ProQuad je cepivo, ki vsebuje oslabljene viruse ošpic, mumpsa, rdečk in noric (varičela).
This vaccine should be given subcutaneously to individuals with thrombocytopenia or any coagulation disorder because bleeding may occur following an intramuscular administration in these individuals. 
Pri posameznikih s trombocitopenijo ali katero koli motnjo koagulacije je treba cepivo injicirati subkutano, saj bi pri intramuskularni aplikaciji lahko prišlo do krvavitev.
In eight clinical studies, the overall rates of adverse reactions after a second dose of ProQuad were generally similar to, or lower than, those seen with the first dose. 
Otroci, ki so bili cepljeni z drugim odmerkom cepiva ProQuad V osmih kliničnih študijah je bil skupni delež neželenih učinkov po drugem odmerku cepiva ProQuad na splošno podoben ali manjši od tistega po prvem odmerku.
ProQuad is not to be injected directly into any blood vessel. 
Cepiva Proquad se ne sme injicirati neposredno v katero koli žilo.
At least 1 month should elapse between receipt of a live virus vaccine and ProQuad. 
Med cepljenjem z živim virusnim cepivom in cepljenjem s cepivom ProQuad mora miniti najmanj 1 mesec.
Clinical studies have demonstrated that ProQuad can be given simultaneously (but at separate injection sites) with Prevenar and/or hepatitis A vaccine, or with monovalent or combination vaccines comprised of diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, or hepatitis B antigen. 
Klinične študije so pokazale, da se cepivo ProQuad lahko da sočasno (vendar se mora injicirati na drugo mesto) s cepivom Prevenar in/ali cepivom proti hepatitisu A ali z monovalentnimi ali s kombiniranimi cepivi proti davici, tetanusu, oslovskemu kašlju (acelularno), Haemophilusu influenzae tipa b, otroški paralizi (inaktivirano) ali s cepivom z antigenom virusa hepatitisa B. V teh kliničnih študijah se je pokazalo, da se imunski odziv ni spremenil.
In three of these studies, the rates of injection-site erythema and swelling were statistically significantly higher after the second dose than after the first dose; however, in the remaining five studies, the rates of each of these reactions were similar after the first and second dose. 
V treh od teh študij je bil delež eritema in otekline na mestu injiciranja statistično značilno večji po drugem odmerku kot po prvem odmerku.
Febrile seizures have been reported in children receiving ProQuad. 
Pri otrocih, ki so prejeli cepivo ProQuad, so poročali o vročinskih krčih.
ProQuad may be used as the second dose in individuals who have previously received measles, mumps, and rubella vaccine and varicella vaccine. 
Cepivo ProQuad lahko uporabimo kot drugi odmerek cepljenja pri posameznikih, ki so bili že cepljeni s cepivom proti ošpicam, mumpsu in rdečkam in cepivom proti noricam.
The only vaccine-related systemic adverse reactions reported at a significantly greater rate in individuals who received the earlier formulation of ProQuad compared to individuals who received the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. and Varicella Vaccine live (Oka/Merck) were fever (≥39.4°C rectal equivalent or abnormal) and measles-like rash. 
Edina s cepljenjem povezana sistemska neželena učinka, o katerih so značilno pogosteje poročali pri otrocih, ki so dobili predhodno obliko cepiva ProQuad, v primerjavi s posamezniki, ki so prejeli cepivo proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc. in cepivo z živim virusom noric (Oka/Merck), sta bila zvišana telesna temperatura (ekvivalentno ≥ 39,4 °C rektalno ali nenormalna) ter ošpicam podoben izpuščaj.
• Common (may affect up to 1 in 10 people): injection site complaints including swelling or bruising; irritability; rash (including measles-like rash, varicella-like rash, and injection-site rash); upper respiratory infection; vomiting and diarrhoea. 
• Pogosti (pojavijo se lahko pri največ 1 od 10 oseb): težave na mestu injiciranja, vključno z otekanjem ali modricami; razdražljivost; izpuščaj (vključno z ošpicam podobnim izpuščajem, noricam podobnim izpuščajem in izpuščajem na mestu injiciranja); okužbe zgornjih dihal; bruhanje in driska.
The immunogenicity and safety of ProQuad were evaluated in a clinical trial involving 799 subjects 4 through 6 years of age who had received Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. at least 1 month prior to study entry. 
Imunogenost in varnost cepiva ProQuad so ocenjevali v kliničnem preskušanju s 799 otroci, starimi 4 do 6 let, ki so bili najmanj 1 mesec pred vstopom v študijo cepljeni s cepivom z živim virusom noric (Oka/Merck) in cepivom proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc.
Keep the vial of powder in the outer carton to protect from light. 
Vialo s praškom shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Agitation, Apathy, Clinging, Emotional changes, Nervousness, Restlessness 
Psihiatrične motnje razdražljivost pogosti jok, nespečnost, motnje spanja občasni agitacija, apatija, oklepanje staršev, čustvene spremembe, nervoznost, nemir redki
ProQuad - Powder in vial and solvent in vial - Pack of 1, 10 
ProQuad - prašek v viali in vehikel v viali - pakiranje po 1, 10
Mumps virus 
Virus noric
ProQuad is given by injection as follows: 
S cepivom ProQuad se cepi po naslednji shemi:
Sucrose, hydrolysed gelatin, urea, sodium chloride, sorbitol, monosodium glutamate, sodium phosphate, sodium bicarbonate, potassium phosphate, potassium chloride, medium 199 with Hanks' Salts, MEM, neomycin, phenol red, HCl, NaOH. 
Saharoza, hidrolizirana želatina, sečnina, natrijev klorid, sorbitol, mononatrijev glutamat, natrijev fosfat, natrijev hidrogenkarbonat, kalijev fosfat, kalijev klorid, medij 199 s Hanksovimi solmi, MEM, neomicin, fenol rdeče, HCl, NaOH.
No clinical data are available for ProQuad administered after exposure to measles, mumps, rubella, or varicella. 
Ni kliničnih podatkov o cepljenju s cepivom ProQuad po izpostavitvi ošpicam, mumpsu, rdečkam ali noricam.
ProQuad with Solvent for reconstitution supplied in a Pre-filled syringe: 
Cepivo ProQuad z vehiklom za rekonstitucijo v napolnjeni injekcijski brizgi:
In such cases, individuals should receive a second dose of ProQuad, given a minimum of 3 months apart, to ensure optimal protection against measles and varicella (see sections 4.4 and 5.1). 
Za zagotovitev optimalne zaščite proti ošpicam in noricam morajo v teh primerih posamezniki prejeti drugi odmerek cepiva ProQuad najmanj 3 mesece po prvem cepljenju (glejte poglavji 4.4 in 5.1).
The only vaccine related injection-site adverse reaction that was more frequent among recipients of ProQuad than among recipients of Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck & Co. Inc. was rash at the injection site. 
Edini s cepljenjem povezan neželen učinek, ki je bil pri prejemnikih cepiva ProQuad pogostejši kot pri prejemnikih cepiva z živim virusom noric (Oka/Merck) in cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., je bil izpuščaj na mestu injiciranja.
- If you get any of the side effects, talk to your doctor or pharmacist. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and gender, being greatest in adult females and least in prepubertal children. 
Artralgija in/ali artritis (običajno prehodna in redko kronična) ter polinevritis so značilni za okužbo z divjim sevom rdečk.
Additionally, other adverse events have been reported with postmarketing use of ProQuad and/or in clinical studies and post-marketing use of either the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., the monovalent component vaccines of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., or Varicella Vaccine live (Oka/Merck). 
Dodatno so na voljo podatki o neželenih učinkih iz obdobja trženja cepiva ProQuad in/ali iz kliničnih študij in iz obdobja trženja cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., enovalentnih komponent cepiv proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., in cepiva z živim virusom noric (Oka/Merck).
ProQuad elicits rates of antibody responses against measles, mumps, and rubella similar to those observed after vaccination with the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. 
Cepivo ProQuad vzpodbudi protitelesni odziv proti ošpicam, mumpsu in rdečkam, ki je podoben kot po cepljenju s cepivom proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc.
What ProQuad contains 
Kaj vsebuje cepivo ProQuad
Other side effects have been reported with the use of at least one of the following: ProQuad, previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by Merck & Co., Inc., or Varicella Vaccine live (Oka/Merck). 
O drugih neželenih učinkih so poročali pri uporabi vsaj enega od naslednjih cepiv: cepiva ProQuad, prejšnjih oblik enovalentnih in kombiniranih cepiv proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., ali cepiva z živim virusom noric (Oka/Merck).
3 Oka/Merck strain (live, attenuated) ...................not less than 3.99 log10 PFU** 
3, sev Oka/Merck (živ, oslabljen).......................najmanj 3,99 log10 PFU**
1 vial (powder) + 1 vial (solvent). 
prašek in vehikel za suspenzijo za injiciranje 1 viala (prašek) + 1 viala (vehikel) 10 vial (prašek) + 10 vial (vehikel)
Widespread use of a 2-dose vaccination schedule in the United States and countries such as Finland and Sweden has led to a >99% reduction in the incidence of each of the 3 targeted diseases. 
Po svetu so med letoma 1978 in 2007 razdelili več kot 518 milijonov odmerkov cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc. Razširjena uporaba cepljenja z 2 odmerkoma v ZDA in državah, kot sta Finska in Švedska, je vodila v > 99-odstotno zmanjšanje pojavnosti vsake od teh treh bolezni.
Afebrile convulsions or seizures, Bell's palsy, Cerebrovascular accident, Dizziness, Dream abnormality, Encephalopathy*, Guillain-Barré syndrome, Measles inclusion body encephalitis (see section 4.3), Ocular palsies, Paraesthesia, Polyneuritis, Polyneuropathy, Subacute sclerosing panencephalitis*, Syncope, Transverse myelitis, Tremor 
Bolezni živčevja vročinski krči*, zaspanost občasni ataksija, konvulzije, glavobol, kričeč jok, hiperkinezija, hipersomnija, letargija, tremor redki nevročinski krči ali napadi, Bellova pareza, možganskožilni dogodek, omotica, nenormalne sanje, encefalopatija*, Guillain-Barréjev sindrom, ošpični encefalitis z inkluzijskimi telesci (glejte poglavje 4.3), očesne paralize, parestezija, polinevritis, polinevropatija, subakutni sklerozirajoči panencefalitis*, sinkopa, transverzni mielitis, tremor neznana pogostnost
Sucrose, hydrolysed gelatin, urea, sodium chloride, sorbitol, monosodium glutamate, sodium phosphate, sodium bicarbonate, potassium phosphate, potassium chloride, medium 199 with Hanks' Salts, MEM, neomycin, phenol red, hydrochloric acid and sodium hydroxide. 
Prašek saharoza, hidrolizirana želatina, sečnina, natrijev klorid, sorbitol, mononatrijev glutamat, natrijev fosfat, natrijev hidrogenkarbonat, kalijev fosfat, kalijev klorid, medij 199 s Hanksovimi solmi, MEM, neomicin, fenol rdeče, klorovodikova kislina in natrijev hidroksid
Following the dose of ProQuad, GMTs for measles, mumps, rubella, and varicella were similar to those following a second dose of Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. administered concomitantly at separate injection sites. 
Po cepljenju s cepivom ProQuad so bila GMT za ošpice, mumps, rdečke in norice podobna kot po drugem odmerku cepiva z živim virusom noric (Oka/Merck) ter cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., s katerima so bili cepljeni sočasno na različnih vbodnih mestih.
The doctor has a more complete list of side effects for ProQuad and for the vaccine components for ProQuad (the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. and Varicella Vaccine live (Oka/Merck)). 
Zdravnik ima podrobnejši seznam neželenih učinkov cepiva ProQuad in posameznih komponent, ki sestavljajo cepivo ProQuad (cepivo proti ošpicam, mumpsu in rdečkam, izdelovalca Merck & Co., Inc., in cepivo z živim virusom noric (Oka/Merck)).
In a clinical trial of ProQuad administered concomitantly with Infanrix Hexa, the rates of fever (≥38.0°C rectal equivalent) were 69.3% following concomitant administration, 61.1% following ProQuad alone, and 57.3% following Infanrix Hexa alone; the rates of fever (≥39.4°C rectal equivalent) were 22.6% following concomitant administration, 20.5% following ProQuad alone, and 15.9% following Infanrix Hexa alone. 
V kliničnem preskušanju s cepivom ProQuad, danim sočasno s cepivom Infanrix Hexa, je po cepljenju z obema cepivoma delež zvišane telesne temperature (ekvivalentno ≥ 38,0 °C rektalno) znašal 69,3 % , po cepljenju samo s cepivom ProQuad 61,1 % in po cepljenju samo s cepivom Infanrix Hexa 57,3 %.
The vaccine response rate was 90.9% (range 80.8% to 94.5%) for varicella based on a post-vaccination antibody titer ≥5 gpELISA units/ml (an antibody titer that has been shown to be highly correlated with long-term protection). 
Delež odziva na cepljenje s post-vakcinacijskim titrom protiteles ≥ 5 gpELISA enot/ml (titer protiteles, ki dokazano dobro sovpada z dolgoročno zaščito), je znašal 90,9 % (razpon od 80,8 % do 94,5 %).
ProQuad is given to help protect your child against measles, mumps, rubella, and varicella (chickenpox). 
Cepljenje s cepivom ProQuad pomaga zaščititi vašega otroka pred ošpicami, mumpsom, rdečkami in noricami (varičelo).